Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.20
-0.25 (-0.63%)
May 8, 2026, 1:58 PM CST
Market Cap1.68B +4.6%
Revenue (ttm)1.21M -28.5%
Net Income-97.47M
EPS-2.26
Shares Out42.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume210,224
Average Volume809,385
Open39.45
Previous Close39.45
Day's Range38.80 - 39.90
52-Week Range29.25 - 57.00
Beta0.45
RSI54.45
Earnings DateAug 12, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 15
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2025, TPEX:7427's revenue was 1.21 million, a decrease of -28.49% compared to the previous year's 1.69 million. Losses were -97.47 million, -7.10% less than in 2024.

Financial Statements